We previously showed that high peritumoral TLS density in the primary tumor predicted response to later anti–PD-1 antibody treatment and subsequent survival, highlighting the clinical benefit of TLS evaluation in initial specimens from patients with recurrent esophageal cancer [23]. This evidence concerns the gene PDCD1 and esophageal cancer.